Stemsynergy Announces Breakthrough in Treating Sarcomas With Its Novel Anti-Wnt Compound  
8/9/2013 8:48:39 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIAMI--(BUSINESS WIRE)--Stemsynergy Therapeutics, Inc., today announced a breakthrough study for treating synovial sarcoma, an aggressive soft tissue cancer that predominantly affects teenagers and young adults. Stemsynergy is a privately held biopharmaceutical company that focuses on the discovery and development of small-molecule drugs targeting developmental pathways fundamental to cancer. Synovial sarcoma is a high-grade soft tissue cancer that is associated with a chromosomal rearrangement, meaning that chromosomes incorrectly switch positions. This results in production of a protein known as “oncogene SYT-SSX.” This protein promotes the uncontrolled cell proliferation that leads to cancer. The 10-year survival rate for individuals with synovial sarcoma is estimated to be as low as 10%. Previously, it was unknown how SYT-SSX caused cancer in people. In a recent study, published in Cancer Discovery, a group from Vanderbilt University Medical Center and Stemsynergy used mice to show that the SYT-SSX oncogene leads to the activation of a cell signaling process called the “Wnt pathway.” This work demonstrated that the Wnt signaling pathway is a master controller for the initiation and growth of synovial sarcomas, and that blocking this pathway can stop tumors from growing.

Help employers find you! Check out all the jobs and post your resume.